Unlike breast and gastric cancers, human HER2‐mutant NSCLC—accounting for approximately 3% of nonsquamous NSCLC cases—is typically treated with chemotherapy or immunotherapy (Table 1). Here, ERBB2 is linked to gastric cancer.